[vc_row][vc_column][vc_column_text]
Simergent
Management Team: Oklahoma City, OK
Steve Lindo
[email protected]
Rick Pendergraft
[email protected]
Potential Partners
Insurance Companies / Payers
Medical Device OEMs
Baxter Healthcare (70% mkt share)
Fresenius (20% market share)
Outset Medical
Medtronic
Dialysis Clinic Organizations
DaVita, Fresenius
Medica Santa Carmen (Mexico)
Revenue Model
Razors / Razor blades
Device drives sales of disposables
Executive Summary
The Problem
Dialysis patients consume 7.1% of the entire Medicare budget at $34B annually. In addition, there are 2.3 million patients who die each year
in emerging markets because they either can’t afford or access dialysis therapy. There is a tremendous need for an affordable, easy to use home dialysis system. Automated peritoneal dialysis can address the accessibility problem and allow patients to perform dialysis in their homes while they sleep, but those dialysis machines cost up to $20,000 plus recurring disposables costs,
which is out of reach for many payers’ budgets.
Our Solution
Simergent is developing a home dialysis system which delivers therapy to a sleeping patient each night. Our automated peritoneal dialysis (APD) device focuses on specific needs for dialysis patients. It supports faster training with fewer nursing staff using a color touch screen. Our technology enables our dialysis device cost to be up to 85% less expensive than traditional home
devices, allowing the home nocturnal dialysis market to save billions in healthcare costs, while delivering safe and effective therapy more quickly than currently available devices.
Target Market
We worked with an internationally recognized market research firm to conduct global market research. Peritoneal Dialysis (PD) is growing at 20% per year in certain emerging markets as countries realize the cost savings potential and quality of life benefits of APD over hemodialysis. Today, PD has a $3.9B total addressable market, with the USA accounting for 43% of that market. Interviews conducted in the USA, Latin America, and Asia all confirmed the need for our affordable APD system. We intend to launch first in the USA, then expand to Mexico, China, India, and other markets based on regulatory approval timelines. Our therapy is 40%-85% less expensive than therapy offered by currently available devices.
Target patients for our device:
New and existing peritoneal dialysis patients
New patients who would have gone on hemodialysis (HD)
IP Strategy
Provisional patent filed enabling superior flow rates at low cost
Trade secret fluid management technology enables superior
accuracy at very low cost
Additional patents to be filed
Regulatory Pathway
FDA 510(k) Class II device clearance expected in early 2020
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_video link=”https://vimeo.com/303601948″][/vc_column][/vc_row]